Skip to content
Licensed Unlicensed Requires Authentication Published by De Gruyter March 26, 2019

Endometriosis and the menopause: why the question merits our full attention

Lydia Marie-Scemama, Marc Even, Jean Bouquet De La Joliniere and Jean-Marc Ayoubi

Abstract

As an estrogen-dependent disease, endometriosis was thought to become less active or regress with the onset of the menopause. However, based on some new data, we are discovering that this pathology can emerge or reappear at this period of life. Clinicians must consider it as a possible cause for cases of pelvic pain, and heavy bleeding. Authors have described a possibility of transformation of the intraperitoneal proliferation into a malignant type with ovarian, bowel and even lung metastasis. The risk of transformation into an ovarian cancer is around 2 or 3%. The role of menopausal hormonal therapy will be discussed as in recurrence in the case of residue existence, especially after incomplete surgery. Is it possible to prescribe hormonal therapy to a menopausal women suffering climacteric symptoms as it could trigger a recurrence of endometriosis and even an increased risk of malignant degeneration? This remains unclear. It is an unresolved therapeutic dilemma; the choice between surgery or medical treatment?

References

[1] Sampson JA. Metastatic or embolic endometriosis due to premenstrual dissemination of endometrial tissue into the peritoneal cavity. Am J Obstet Gynecol. 1927;3:93–110.Search in Google Scholar

[2] Vercellini P, Vigano P, Somigliana E, Fedele L. Endometriosis: pathogenesis and treatment. Nat Rev Endocrinol. 2014;10:261–75.10.1038/nrendo.2013.255Search in Google Scholar PubMed

[3] Burney RO, Talbi S, Hamilton AE, Vo KC, Nezhat CR, Lessey BA, et al. Gene expression analysis of endometrium reveals progesterone resistance and candidate susceptibility genes in women with endometriosis. Endocrinology. 2007;148:3814–26.10.1210/en.2006-1692Search in Google Scholar PubMed

[4] Santulli P, Borghese B, Noel JC, Fayt I, Anaf V, de Ziegler D, et al. Hormonotherapy deregulates prostaglandin-endoperoxidase synthase (PTGS2) expression in endometriotic tissues. J Clin Endocrinol Metab. 2014;99:881–90.10.1210/jc.2013-2950Search in Google Scholar PubMed

[5] Santulli P, Chouzenoux S, Fiorese M, Marcellin L, Lemarechal H, Millischer AE, et al. Protein oxidative stress markers in peritoneal fluids of women with deep infiltrating endometriosis are increased. Hum Reprod. 2015;30:49–60.10.1093/humrep/deu290Search in Google Scholar PubMed

[6] Leconte M, Nicco C, Ngo C, Chereau C, Chouzenoux S, Marut W, et al. The mTOR/AKT inhibitor temsirolimus prevents deep infiltrating endometriosis in mice. Am J Pathol. 2011;179:880–9.10.1016/j.ajpath.2011.04.020Search in Google Scholar PubMed PubMed Central

[7] Ngo C, Nicco C, Leconte M, Chereau C, Arkwright S, VAcher Lavenu MC, et al. Protein kinase inhibitors can control the progression of endometriosis in vitro and in vivo. J Pathol. 2010;222:148–57.10.1002/path.2756Search in Google Scholar PubMed

[8] Borghese B, Tost J, de Surville M, Busato F, Letourneur F, Mondon F, et al. Identification of susceptibility genes for peritoneal, ovarian, and deep infiltrating endometriosis using a pool sample-based genome-wide association study. Biomed Res Int. 2015;2015:461024.10.1155/2015/461024Search in Google Scholar PubMed PubMed Central

[9] Nyholt DR, Low SK, Anderson CA, Painter JN, Uno S, Morris AP, et al. Genome-wide association meta-analysis identifies new endometriosis risk loci. Nat Genet. 2012;44:1355–9.10.1038/ng.2445Search in Google Scholar PubMed PubMed Central

[10] Pagliardini L, Gentilini D, Vigano P, Panina-Bordignon P, Busacca M, Candiani M, et al. An Italian association study and meta-analysis with previous GWAS confirm WNT4, CDKN2BAS and FN1 as the first identified susceptibility loci for endometriosis. J Med Genet. 2013;50:43–6.10.1136/jmedgenet-2012-101257Search in Google Scholar PubMed

[11] Borghese B, Barbaux S, Mondon F, Santulli P, Pierre G, Vinci G, et al. Research resource: genome wide profiling of methylated promoters in endometriosis. Mol Endocrinol. 2010;24:1872–85.10.1210/me.2010-0160Search in Google Scholar PubMed PubMed Central

[12] Umezawa M, Sakata C, Tanaka N, Tabata M, Takeda K, Ihara T, et al. Pathological study for the effects of in utero and postnatal exposure to diesel exhaust on a rat endometriosis model. J Toxicol Sci. 2011;36:493–8.10.2131/jts.36.493Search in Google Scholar

[13] Bendon CL, Becker CM. Potential mechanisms of postmenopausal endometriosis. Maturitas. 2012;72:214–19.10.1016/j.maturitas.2012.04.010Search in Google Scholar

[14] Bulun SE. Endometriosis. N Engl J Med. 2009;360:268–79.10.1016/B978-0-323-47912-7.00025-1Search in Google Scholar

[15] Bulun SE, Yang S, Fang Z, Gurates B, Tamura M, Sebastian S. Estrogen production and metabolism in endometriosis. Ann N Y Acad Sci. 2002;955:396–406.10.1111/j.1749-6632.2002.tb02767.xSearch in Google Scholar

[16] Tan DA, Almaria MJ. Postmenopausal endometriosis: drawing a clearer clinical picture. Climateric. 2018;21:249–55.10.1080/13697137.2018.1450855Search in Google Scholar

[17] Haas D, Chvatal R, Reichert B, Rennert S, Shebl O, Binder H, et al. Endometriosis: a premenopausal disease? Arch Gynecol Obstet. 2012;286:667–70.10.1007/s00404-012-2361-zSearch in Google Scholar

[18] Gemmell LC, Webster KE, Kirtley S, Vincent K, Zondervan KT, Becker CM. The management of menopause in women with a history of endometriosis: a systematic review. Human Reprod Update. 2017;23:481–500.10.1093/humupd/dmx011Search in Google Scholar

[19] Soliman NF, Hillard TC. Hormone replacement herapy in women with past history of endometriosis. Climateric. 2006;9:325–35.10.1080/13697130600868711Search in Google Scholar

[20] Al Kadri H, Hassan S, Al-Fozan HM, Hajeer A. Hormone therapy for endometriosis and surgical menopause. Cochrane Database Syst Rev. 2009. DOI: 10.1002/14651858.CD005997.pub2.Search in Google Scholar

[21] Fedele L, Bianchi S, Raffaelli R, Zanconato G. Comparison of transdermal estradiol and tibolone for the treatment of oophorectomized women with deep residual endometriosis. Fert Steril. 1989;51:781–5.10.1016/S0378-5122(99)00032-8Search in Google Scholar

[22] Moen MH, Rees M, Brincat M, Erel T, Gambacciani M, Lambrinoudaki I, et al. European Menopause and Andropause Society. EMAS position statement: managing the menopause in women with a past history of endometriosis. Maturitas. 2010;67:94–7.10.1016/j.maturitas.2010.04.018Search in Google Scholar PubMed

[23] Stern RC, Dash R, Bentley RC, Snyder MJ, Haney AF, Robboy SJ. Malignancy in endometriosis: frequency and comparison of ovarian and extraovarian types. Int J Gynecol Pathol. 2001;20:133–9.10.1097/00004347-200104000-00004Search in Google Scholar PubMed

[24] Melin A, Sparen P, Perrson I, Bergqvist A. Endometriosis and the risk of cancer with special emphasis on ovarian cancer. Human Reprod. 2006;21:1237–42.10.1093/humrep/dei462Search in Google Scholar PubMed

[25] Audebert A. Women with endometriosis: are they different from others? Gynecol Obstet Fertil. 2005;33:239–46.10.1016/j.gyobfe.2005.03.010Search in Google Scholar PubMed

[26] Chene G. Is endometriosis a pre-cancerous lesion Perspectives Implications Cliniques. Gynécol Obstét Fertilité 2016.10.1016/j.gyobfe.2016.01.001Search in Google Scholar PubMed

[27] Inceboz U. Endometriosis after menopause. Womens Health (Lond). 2015;11:711–15.10.2217/whe.15.59Search in Google Scholar PubMed

[28] Streuli I, Gaitzch H, Wenger JM, Petignat P. Endometriosis after menopause: physiopathology and management of an uncommon condition. Climateric. 2017;20:138–43.10.1080/13697137.2017.1284781Search in Google Scholar PubMed

[29] Polyzos NP, Fatemi HM, Zavos A, Papanikolau EG. Aromatase inhibitors in post menopausal endometriosis. Reprod Biol Endocrinol. 2011;9:90.10.1186/1477-7827-9-90Search in Google Scholar PubMed PubMed Central

Received: 2018-10-20
Accepted: 2019-01-20
Published Online: 2019-03-26

©2019 Walter de Gruyter GmbH, Berlin/Boston

Scroll Up Arrow